Upgrade to SI Premium - Free Trial

BMO Capital on Pfizer (PFE): 'SigVie Trial Misses on OS With Signs of Benefit for Future Trials'

June 23, 2026 8:44 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $34.00 price target on Pfizer (NYSE: PFE).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments